The TAVR is a real, true, bona fide miracle of modern medicine. And it isn’t simple at all.

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.

Low-risk patients with severe, symptomatic aortic stenosis show similar clinical outcomes and valve durability ...

Medtronic today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.

Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards Lifesciences has seen its consensus analyst price target inch higher, rising from $87.73 to $88.83 as market ...

SAN FRANCISCO -- Better indicators of high-grade atrioventricular (AV) conduction system abnormalities following transcatheter aortic valve replacement (TAVR) could be gleaned from an intraprocedural ...

Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly ...

Edwards’ Q3 revenues were chiefly driven by a 12.4% uplift in its transcatheter aortic valve replacement (TAVR) product group ...